Thermogenesis holdings announces that immunecyte joint venture receives $3 mln equity investment

Thermogenesis holdings announces that immunecyte joint venture receives $3.0 million equity investment.thermogenesis - investor received 600,000 shares of class a stock at $5.00/share, representing a 5.66% ownership in jv.thermogenesis - after investment, immunecyte is owned 75.47% by healthbanks biotech (usa), 18.87% by co, 5.66% by the private institution.thermogenesis holdings - because of equity investment in immunecyte, co' equity in jv is no longer subject to anti-dilution provision.
THMO Ratings Summary
THMO Quant Ranking